Pharmaceutical company Alkermes is among the backers to benefit from Celgene's investment, which was made at three times the value of Acceleron's IPO in September.

Celgene, a pharmaceutical company engaged primarily in the discovery, development and commercialisation of therapies for the treatment of cancer and inflammatory diseases, has increased its stake in US-based biopharmaceutical company Acceleron to 15%, according to FierceBiotech.

Celgene bought 1.1 million shares for Acceleron from biopharmaceutical company Alkermes, Flagship Ventures, Polaris Ventures, Venrock Associates, Advanced Technology Ventures, enabling those investors to collectively cash out a $47m stake.

The company bought the shares for a price close to a triple the $15…